Table 2.
Proportion of all patients and patients with recurrence/metastasis and CD44/CD24 data with CD44+/CD24-/low tumor cells
| n | All cases (%) | P | n | Recurrence/metastatic cases (%) | P* | |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| < 50 |
74 |
18.34 ± 2.70 |
0.444 |
34 |
24.91 ± 3.79 |
0.022 |
| ≥ 50 |
73 |
15.45 ± 2.66 |
|
38 |
13.20 ± 3.32 |
|
| Tumor size | ||||||
| T1 |
47 |
15.78 ± 2.86 |
0.224 |
15 |
13.19 ± 3.53 |
|
| T2 |
76 |
20.12 ± 2.90 |
|
44 |
23.78 ± 3.68 |
|
| T3 + T4 |
17 |
10.27 ± 4.46 |
|
13 |
11.83 ± 6.60 |
0.152 |
| Lymph node involvement | ||||||
| Absent |
32 |
8.66 ± 2.70 |
0.026 |
18 |
10.00 ± 3.77 |
0.075 |
| Present |
115 |
19.20 ± 2.29 |
|
54 |
21.53 ± 3.19 |
|
| TNM stage | ||||||
| I + II |
70 |
15.87 ± 2.63 |
0.500 |
33 |
16.88 ± 3.74 |
0.368 |
| III + IV |
77 |
18.49 ± 2.81 |
|
39 |
21.73 ± 3.79 |
|
| ER expression | ||||||
| Negative |
90 |
16.49 ± 2.47 |
0.845 |
47 |
18.92 ± 3.17 |
0.944 |
| Positive |
57 |
17.26 ± 3.07 |
|
25 |
19.32 ± 4.81 |
|
| PR expression | ||||||
| Negative |
83 |
13.09 ± 2.41 |
0.038 |
43 |
14.63 ± 3.06 |
0.046 |
| Positive |
64 |
21.06 ± 2.98 |
|
29 |
25.32 ± 4.51 |
|
| Her2 expression | ||||||
| Negative |
77 |
16.18 ± 3.03 |
0.566 |
38 |
17.36 ± 4.17 |
0.441 |
| Positive |
70 |
18.47 ± 2.61 |
|
34 |
21.57 ± 3.47 |
|
| Basal-like feature † | ||||||
| Absent |
108 |
18.44 ± 2.24 |
0.143 |
49 |
11.70 ± 4.07 |
0.050 |
| Present |
39 |
11.93 ± 3.66 |
|
23 |
22.66 ± 3.30 |
|
| Recurrence or metastasis | ||||||
| Absent |
75 |
14.26 ± 2.72 |
0.246 |
|
|
|
| Present |
72 |
18.73 ± 2.58 |
|
|
|
|
| Lesions in recurrence/metastatic patients | ||||||
| Primary |
|
|
|
56 |
15.39 ± 2.63 |
0.014 |
| Secondary | 16 | 30.41 ± 6.46 | ||||
* Calculated by t tests. ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2.
† Immunohistochemically negative for both SR and Her2.